latest update:
[TrialBase DB]

trial summary · NCT07170293

Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

An Exploratory, Prospective, Single Arm, Open Label, Single Center, Basket, Phase II Clinical Study of Tunlametinib (HL-085) in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors

Trial record from the TrialBase DB dataset, status RECRUITING, condition Solid Cancers, sponsored by Tianjin Medical University Second Hospital. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07170293phase PHASE2enrollment 15start 2027-08-31

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study is a single cohort, open label exploratory clinical trial aimed at observing and evaluating the efficacy and safety of Tunlametinib (HL-085) in the treatment of refractory solid tumors with advanced metastatic non melanoma. It is expected that the ORR of Tunlametinib (HL-085) treatment can reach 20%. According to the literature results, the experimental group rate is 0.2 and the target value rate is 0.02. If the bilateral alpha is 0.05 and the beta is 0.2, the sample size is calculated as 12 cases in the experimental group. Considering a 20% dropout rate, a total of 15 cases are required.

Source record: https://clinicaltrials.gov/study/NCT07170293

Facts

registry idNCT07170293
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionSolid Cancers
sponsorTianjin Medical University Second Hospital
sponsor classOTHER
enrollment15
start date2027-08-31
primary completion2027-09-30
completion2027-09-30
results postednot reported

Conditions

  • Solid Cancers

Interventions

  • Tunlametinib

Countries

  • China

Intervention types: DRUG

Work with this record